BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Katz to Hezbollah chief Qassem: You won't live to see Israel’s full response to Passover attacks - 2Potential Houthi threat to Red Sea shipping could further damage global economy
- 3Grasping Various Kinds of Local misdemeanors
- 4First stop, the Moon. Next stop, Mars? Why Nasa's mission matters
- 5Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover
- Bombardier Global 8000 Enters Service
- A few Exemplary Chinese Dishes, Which Are Famous Around the world
- The Eastern Bongo, Kenya’s Rare Forest Antelope on the Brink
- A hunger for new experiences Narratives: Motivating Travel and Experience
- Oldest evidence of human fire-making discovered at site in England
- Anthony Joshua's driver charged over Nigeria crash that killed two
- AstraZeneca to invest $2 billion as part of US manufacturing push
- In a scientific first, biologists recorded a wild wolf potentially using tools
- Coffee Prices Finish Higher on Brazil Cop Concerns
